Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - PDS Biotechnology Corp | s002158x1_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 28, 2018
Edge Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
|
Delaware
|
001-37568
|
26-4231384
|
|
(State or Other Jurisdiction
of Incorporation or Organization) |
(Commission
File Number) |
(I.R.S. Employer
Identification No.) |
300 Connell Drive, Suite 4000
Berkeley Heights, New Jersey 07922
(800) 208-3343
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 8.01 Other Events
On March 28, 2018, Edge Therapeutics, Inc. (“Edge”) issued a press release announcing that Edge is discontinuing the Phase 3 Newton 2 study based on the recommendation of an independent Data Monitoring Committee (the “DMC”) that Edge stop its Phase 3 NEWTON 2 study. The DMC recommendation was based on its conclusion that that the study has a low probability of meeting its primary endpoint. A copy of the press release is filed herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press Release, dated March 28, 2018.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: March 28, 2018
|
Edge Therapeutics, Inc.
|
|
|
By:
|
/s/ Andrew Saik
|
|
|
Name: Andrew Saik
|
||
|
Title: Chief Financial Officer
|
||